Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22581399 | 0.87 | ALOX15 (0.43) | ALOX15KEAP1SMN1; SMN2 | |
| SCHEMBL24577742 | 0.82 | KDM4E (0.36) | HDAC6MCHR1 | |
| SCHEMBL27284833 | 0.82 | KDM4E (0.36) | HDAC6MCHR1 | |
| SCHEMBL31270210 | 0.79 | L3MBTL1 (0.42) | HDAC6MCHR1 | |
| SCHEMBL14993202 | 0.79 | ALOX15 (0.50) | ALOX15KEAP1SMN1; SMN2 | |
| SCHEMBL17706230 | 0.78 | ALOX15 (0.48) | ALOX15 | |
| SCHEMBL21666874 | 0.78 | MCHR1 (0.31) | MCHR1 | |
| SCHEMBL21620152 | 0.78 | HDAC6 (0.32) | HDAC6MCHR1 | |
| SCHEMBL12312347 | 0.78 | TSHR (0.47) | HDAC6MCHR1 | |
| Hydrochloric Acid SCHEMBL22581302 | 0.77 | KEAP1 (0.38) | ALOX15KEAP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267585-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | Actelion Pharmaceuticals Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022136509-A1 | PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2022-06-30 | — | — | WO | disclosed |